Company intelligence / Profile preview

CiVi Biopharma

Chevy Chase, Maryland, United Statescivibio.com ↗

Ownership: Private
Development stage: Other

Overview

CiVi Biopharma has a Phase 3 clinical trial (AURORA) evaluating intravenous iloprost (CIVI030) for Systemic Sclerosis. Their PCSK9 inhibitor (CIVI008) is in early development with IND filing expected in Q4 2023. The company has also developed the COPE platform for oral delivery of oligonucleotide drugs.

Therapeutic areas: OtherCardiovascularMetabolic DisordersRheumatology
Modalities: Small moleculesAntisense Oligonucleotides (ASO)
Industry: Biotech

Beyond the preview

Go deeper on CiVi Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CiVi Biopharma.